广州艾赛吉

ASG Biotech is a clinical-stage biopharmaceutical company based in Guangzhou, China, specializing in the development of next-generation cell therapies for oncology. The company utilizes a proprietary non-viral gene integration platform that aims to overcome the limitations of traditional viral vectors, such as high manufacturing costs and safety concerns. Their pipeline features several CAR-T and TCR-T candidates targeting both hematological malignancies and challenging solid tumors, including liver and pancreatic cancers. By leveraging advanced genetic engineering and efficient manufacturing processes, ASG Biotech focuses on creating more effective, safer, and affordable immunotherapies for a broad range of cancer patients.